The role of the phosphodiesterase-4 inhibitor, roflumilast, in chronic obstructive pulmonary disease.
作者信息
Wedzicha Jadwiga A
出版信息
Pol Arch Med Wewn. 2010;120(1-2):9-10.
PMID:20150838
Abstract
摘要
相似文献
1
The role of the phosphodiesterase-4 inhibitor, roflumilast, in chronic obstructive pulmonary disease.
Pol Arch Med Wewn. 2010;120(1-2):9-10.
2
What is the role of roflumilast in chronic obstructive pulmonary disease?
Cleve Clin J Med. 2017 Jan;84(1):13-15. doi: 10.3949/ccjm.84a.15150.
3
[Roflumilast: clinical review of a new option for the treatment of inflammation in COPD].
Arch Bronconeumol. 2010 Nov;46 Suppl 9:8-11. doi: 10.1016/S0300-2896(10)70047-8.
4
Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
Lancet. 2015 Mar 7;385(9971):857-66. doi: 10.1016/S0140-6736(14)62410-7. Epub 2015 Feb 13.
5
Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.
Clin Ther. 2012 Jan;34(1):56-66. doi: 10.1016/j.clinthera.2011.12.008.
6
[Clinical profile of roflumilast].
Arch Bronconeumol. 2010 Dec;46 Suppl 10:25-32. doi: 10.1016/S0300-2896(10)70053-3.
7
[Phosphodiesterase-4 inhibitors: roflumilast].
Rev Clin Esp. 2011 Mar;211 Suppl 2:22-30. doi: 10.1016/S0014-2565(11)70008-X.
8
[Phosphodiesterase-4 inhibitors: a new target in treatment of COPD].
Dtsch Med Wochenschr. 2011 Nov;136(44):2267-70. doi: 10.1055/s-0031-1292040. Epub 2011 Oct 25.
9
Roflumilast for chronic obstructive pulmonary disease.
Lancet. 2005 Nov 26;366(9500):1846; author reply 1846-7. doi: 10.1016/S0140-6736(05)67749-5.
10
Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.
Respir Res. 2011 Jan 27;12(1):18. doi: 10.1186/1465-9921-12-18.
Zotero 插件